Janssen Pharmaceutica Nv

Bristol-myers Squibb Compnay

Simon Albert Wagschal

Yi Xiao

Andras Horvath

Bin Zheng

Nicolas Cuniere

Diego Fernando Domenico Broggini

Sergei Kolotuchin

Yu Fan

Cyril Ben Haim

Eric M Simmons

Carolyn S Wei

Cheng Yi Chen

Changxia Yuan

Sebastien Francois Emmanuel Lemaire

Jinxiong Su

Yuanyuan Yuan

Philip James Pye

Amarjit Singh

Shuo Wang

Dominique Paul M Depré

Florian Damien Medina

Thomas Joost Martti Michiels

Duy Chi Trung Cao

Kostiantyn Chernichenko

Cyril Ben Haïm

Subha Mukherjee

Highly efficient methods are provided for preparing key intermediates in the synthesis of Compound (I), which are broadly applicable and can provide selected components having a variety of substituents groups.

Synthetic options towards the manufacture of (6R,10S)-10-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6H)-pyrimidinyl} - 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15-(metheno)pyrazolo[4,3-b][1,7]diazacyclotetradecin-5(6H)-one

Disclosed is a process for the preparation of certain intermediates, e.g. the following compound: which intermediate and processes are useful in the preparation of a BTK inhibitor, such as ibrutinib.

Processes and intermediates for preparing a Btk inhibitor

Disclosed is a process for the preparation of certain intermediates, e.g. a process for preparing a compound of formula (I) wherein, R, Rand Xare as defined in the description, and which intermediate and processes are useful in the preparation of a BTK inhibitor, such as ibrutinib.

Growing community of inventors

Schaffhausen, Switzerland

Simon Albert Wagschal